poisar

Stocks · News reference

Guggenheim Maintains Buy Rating on Roivant Sciences

Fiscal.ai

Guggenheim has reaffirmed its 'Buy' rating for Roivant Sciences, reflecting a continued positive outlook from the firm.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    Roivant Sciences Q2 2027 Earnings Call Transcript

    Roivant Sciences (NASDAQ:ROIV) reported second-quarter financial results on Monday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga